Investors who bought into the first major US neurotech IPO of 2026 were sitting on roughly 22% losses by the end of week one. Mobia Medical, the company behind the only FDA-approved implanted vagus nerve stimulator for chronic stroke recovery, priced its $150 million IPO at $15 per share on 7 May 2026, opened below pricing the next morning on the Nasdaq Global Select Market under the ticker MOBI, and closed week one at $11.75. The print is the cleanest market signal so far for the dozen-plus pre-IPO bioelectronic-medicine companies preparing 2026-27 listings.

The pricing and the first-week trade

Mobia priced 10 million shares at the bottom of its $14-16 indicative range, raising $150 million in gross proceeds. Trading opened on 8 May at $14, below pricing, and never crossed $15 in the first session. The stock drifted lower through the week to close 11 May at $11.75, a roughly 22% decline from the IPO price in three sessions. The offering closed on 11 May. BofA Securities, Piper Sandler and Stifel led the underwriting syndicate.

What Vivistim does

Mobia’s commercial product is the Vivistim Paired VNS System, an implanted pulse generator and lead that delivers timed electrical pulses to the vagus nerve during physical therapy sessions for chronic ischemic stroke patients with moderate-to-severe upper limb impairment. The stimulation is paired with specific arm movements during therapy, with the goal of using vagus nerve activation to amplify neuroplasticity and convert therapy gains into durable functional recovery. The device received FDA approval on 27 August 2021. It is currently the only FDA-approved paired-VNS therapy for chronic stroke recovery.

The MicroTransponder backstory

Mobia is the rebrand of MicroTransponder, an Austin, Texas-based bioelectronic company founded in 2007. The original MicroTransponder name carried through more than a decade of clinical development and the FDA approval cycle. The company rebranded to Mobia Medical in February 2026, four months ahead of its IPO filing, with the new identity intended to anchor commercial expansion and capital markets visibility around the Vivistim brand rather than the legacy technology platform name. The IPO is the company’s first public capital event after nearly two decades of private financing.

What this resets for the pre-IPO bioelectronic-medicine cohort

A cluster of bioelectronic-medicine companies have raised substantial private rounds across 2025-26 and are widely understood to be eyeing 2026-27 listings: SetPoint Medical (vagus nerve stimulation for rheumatoid arthritis), BlueWind Medical (implantable tibial nerve stimulation for overactive bladder, which closed a $47.8 million round on 14 May 2026), Salvia BioElectronics (chronic migraine), Nervonik (peripheral nerve stimulation, $52.5 million Series B on 27 April 2026), and Spark Biomedical (auricular vagus nerve stimulation for opioid withdrawal). Each has been pitching capital partners against an implicit public-comp valuation framework that the Mobia trade now compresses.

The cleanest comp for Mobia is its own category: single-indication, implantable, FDA-approved bioelectronic-medicine companies pursuing direct sales-force commercialisation. The 22% week-one drop suggests public-market investors are pricing those businesses on near-term commercial execution and revenue trajectory rather than on platform-and-pipeline narratives. That posture is consistent with the more cautious medtech IPO market overall, and it raises the bar for the next bioelectronic-medicine company that wants to test public capital.

What to watch

The first signal to watch is MOBI’s trading trajectory through Q2 earnings and the company’s first quarterly print as a public company. Strong Vivistim revenue growth and physician adoption metrics could repair sentiment quickly; a soft Q1 print would compound the IPO underperformance. The second signal is which of the pre-IPO bioelectronic-medicine cohort moves first to file or delay. BlueWind’s 14 May private round in the same week as the Mobia IPO suggests at least one peer chose private capital over public testing. SetPoint and Salvia are the next names to track for any filing activity through the summer.

The broader bioelectronic-medicine commercial inflection Inside BCI tracked on 5 May and extended on 16 May is still moving forward at the clinical and reimbursement level. The Mobia trade is the first reminder that the capital-markets layer above that inflection is not moving in lockstep.

Sources

• Mobia Medical Announces Pricing of Initial Public Offering (Mobia IR, 7 May 2026)
• Mobia Medical Form 424B4 (SEC, May 2026)
• Mobia Medical (previously MicroTransponder) plans IPO (Implantable Device)
• Mobia Medical CEO eyes large market for stroke rehab (MedTech Dive)
• Mobia Medical’s $150 Million IPO (Cleary Gottlieb)
• MicroTransponder Announces Corporate Name Change to Mobia Medical (BioSpace, February 2026)
• MicroTransponder Receives FDA Approval for Breakthrough Device Benefiting Stroke Survivors (PR Newswire, 31 August 2021)
• Mobia Medical (MOBI) Stock Price (Yahoo Finance)